☰

Mohammed Asmal, Ph.D. - Publications

Affiliations: 
2002 Columbia University, New York, NY 
Area:
Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Tisdale JF, Pierciey FJ, Bonner M, Thompson AA, Krishnamurti L, Mapara MY, Kwiatkowski JL, Shestopalov I, Ribeil JA, Huang W, Asmal M, Kanter J, Walters MC. Safety and Feasibility of Hematopoietic Progenitor Stem Cell Collection by Mobilization with Plerixafor Followed by Apheresis vs Bone Marrow Harvest in Patients with Sickle Cell Disease in the Multi-center HGB-206 Trial. American Journal of Hematology. PMID 32401372 DOI: 10.1002/Ajh.25867  0.313
2020 Hsieh MM, Bonner M, Pierciey FJ, Uchida N, Rottman J, Demopoulos L, Schmidt M, Kanter J, Walters MC, Thompson AA, Asmal M, Tisdale JF. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances. 4: 2058-2063. PMID 32396618 DOI: 10.1182/Bloodadvances.2019001330  0.301
2019 Bonner M, Kanter J, Macari E, Lane R, Lewis G, Coles P, Kassenaar S, Mynampati S, Schulze R, Hebert M, Walters MC, Thompson AA, Asmal M, Tisdale JF, Pierciey FJ. The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy Blood. 134: 206-206. DOI: 10.1182/Blood-2019-129124  0.418
2019 Magrin E, Semeraro M, Magnani A, Puy H, Miccio A, Hebert N, Diana J, Lefrere F, Suarez F, Hermine O, Brousse V, Poirot C, Bourget P, El Nemer W, Guichard I, ... ... Asmal M, et al. Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy Blood. 134: 3358-3358. DOI: 10.1182/Blood-2019-127393  0.369
2019 Rasko J, Walters M, Kwiatkowski J, Hongeng S, Porter J, Sauer M, Thrasher A, Thuret I, Schiller G, Elliot H, Deary B, Chen Y, Tao G, Asmal M, Locatelli F, et al. Efficacy and safety of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies Cytotherapy. 21: S14. DOI: 10.1016/J.Jcyt.2019.03.578  0.353
2019 Anurathapan U, Locatelli F, Kwiatkowski JL, Rasko JE, Schiller GJ, Porter J, Sauer MG, Thrasher AJ, Chabannon C, Elliot H, Deary B, Chen Y, Tao G, Asmal M, Thompson AA, et al. Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Outcomes from the Phase 1/2 Northstar and Phase 3 Northstar-2 Studies Biology of Blood and Marrow Transplantation. 25: S66-S67. DOI: 10.1016/J.Bbmt.2018.12.150  0.365
2019 Mapara MY, Tisdale JF, Kanter J, Kwiatkowski JL, Krishnamurti L, Schmidt M, Miller AL, Pierciey FJ, Shi W, Ribeil J, Asmal M, Thompson AA, Walters MC. Lentiglobin Gene Therapy in Patients with Sickle Cell Disease: Updated Interim Results from Hgb-206 Biology of Blood and Marrow Transplantation. 25: S64-S65. DOI: 10.1016/J.Bbmt.2018.12.147  0.374
2018 Esrick EB, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney MM, London WB, Biasco L, Asmal M, Williams DA, Biffi A. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances. 2: 2505-2512. PMID 30282642 DOI: 10.1182/Bloodadvances.2018016725  0.411
2018 Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, ... ... Asmal M, et al. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. The New England Journal of Medicine. 378: 1479-1493. PMID 29669226 DOI: 10.1056/Nejmoa1705342  0.394
2018 Tisdale JF, Kanter J, Mapara MY, Kwiatkowski JL, Krishnamurti L, Schmidt M, Miller AL, Pierciey FJ, Shi W, Ribeil J, Asmal M, Thompson AA, Walters MC. Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study Blood. 132: 1026-1026. DOI: 10.1182/Blood-2018-99-113480  0.374
2018 Locatelli F, Walters MC, Kwiatkowski JL, Porter J, Sauer MG, Thuret I, Hongeng S, Kulozik AE, Lal A, Thrasher AJ, Yannaki E, Elliot H, Tao G, Asmal M, Thompson AA. Lentiglobin Gene Therapy for Patients with Transfusion-Dependent β-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies Blood. 132: 1025-1025. DOI: 10.1182/Blood-2018-99-112667  0.36
2018 Rasko JE, Thompson AA, Kwiatkowski JL, Hongeng S, Schiller GJ, Anurathapan U, Cavazzana M, Ho PJ, Schmidt M, Kletzel M, Leboulch P, Vichinsky E, Deary B, Chen Y, Asmal M, et al. Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study Blood. 132: 167-167. DOI: 10.1182/Blood-2018-167  0.373
2018 Tisdale JF, Kanter J, Hsieh M, Krishnamurti L, Kwiatkowski JL, Kamble RT, von Kalle C, Miller A, Pierciey FJ, Shi W, Asmal M, Thompson AA, Walters MC. Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell Disease Biology of Blood and Marrow Transplantation. 24: S174. DOI: 10.1016/J.Bbmt.2017.12.108  0.339
2017 Tisdale JF, Pierciey FJ, Kamble R, Kanter J, Krishnamurti L, Kwiatkowski JL, Thompson AA, Shestopalov I, Bonner M, Joseney-Antoine M, Asmal M, Walters MC. Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease Blood. 130: 990-990. DOI: 10.1182/Blood.V130.Suppl_1.990.990  0.429
2017 Walters MC, Hongeng S, Kwiatkowski JL, Locatelli F, Porter JB, Sauer MG, Thrasher AJ, Thuret I, Yannaki E, Elliot H, Gayron M, Asmal M, Thompson AA. Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients with Non-β0/β0 Genotypes Blood. 130: 526-526. DOI: 10.1182/Blood.V130.Suppl_1.526.526  0.393
2017 Kwiatkowski JL, Thompson AA, Rasko J, Hongeng S, Schiller GJ, Anurathapan U, Cavazzana M, Ho PJ, Kalle Cv, Kletzel M, Leboulch P, Vichinsky E, Deary B, Asmal M, Walters MC. Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study Blood. 130: 360-360. DOI: 10.1182/Blood.V130.Suppl_1.360.360  0.375
2016 Krebs KC, Tian M, Asmal M, Ling B, Nelson K, Henry K, Gibson R, Li Y, Han W, Shattock RJ, Veazey RS, Letvin N, Arts EJ, Gao Y. Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. Aids Research and Therapy. 13: 41. PMID 27906032 DOI: 10.1186/S12981-016-0125-8  0.316
2016 Asmal M, Lane S, Tian M, Nickel G, Venner C, Dirk B, Dikeakos J, Luedemann C, Mach L, Balachandran H, Buzby A, Rao S, Letvin N, Gao Y, Arts EJ. Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections. Virology. 499: 298-312. PMID 27723488 DOI: 10.1016/J.Virol.2016.09.021  0.364
2016 Ribeil J, Hacein-Bey-Abina S, Payen E, Semeraro M, Elisa M, Caccavelli L, Touzot F, Lefrere F, Suarez F, Hermine O, Brousse V, Poirot C, Neven B, Bourget P, El Nemer W, ... ... Asmal M, et al. Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies Blood. 128: 2311-2311. DOI: 10.1182/Blood.V128.22.2311.2311  0.396
2016 Kanter J, Walters MC, Hsieh MM, Krishnamurti L, Kwiatkowski J, Kamble RT, von Kalle C, Kuypers FA, Cavazzana M, Leboulch P, Joseney-Antoine M, Asmal M, Thompson AA, Tisdale JF. Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease Blood. 128: 1176-1176. DOI: 10.1182/Blood.V128.22.1176.1176  0.392
2016 Thompson AA, Kwiatkowski J, Rasko J, Hongeng S, Schiller GJ, Anurathapan U, Cavazzana M, Ho PJ, von Kalle C, Kletzel M, Leboulch P, Vichinsky E, Petrusich A, Asmal M, Walters MC. Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study Blood. 128: 1175-1175. DOI: 10.1182/Blood.V128.22.1175.1175  0.373
2015 Asmal M, Luedemann C, Lavine CL, Mach LV, Balachandran H, Brinkley C, Denny TN, Lewis MG, Anderson H, Pal R, Sok D, Le K, Pauthner M, Hahn BH, Shaw GM, et al. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology. 475: 37-45. PMID 25462344 DOI: 10.1016/J.Virol.2014.10.032  0.32
2013 Kolodkin-Gal D, Hulot SL, Korioth-Schmitz B, Gombos RB, Zheng Y, Owuor J, Lifton MA, Ayeni C, Najarian RM, Yeh WW, Asmal M, Zamir G, Letvin NL. Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus. Journal of Virology. 87: 13589-97. PMID 24109227 DOI: 10.1128/Jvi.03108-12  0.359
2012 Asmal M, Whitney JB, Luedemann C, Carville A, Steen R, Letvin NL, Geiben-Lynn R. In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes. Plos One. 7: e48234. PMID 23133620 DOI: 10.1371/Journal.Pone.0048234  0.341
2012 Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. Journal of Virology. 86: 7760-70. PMID 22593152 DOI: 10.1128/Jvi.00599-12  0.351
2011 Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, ... ... Asmal M, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. Plos Pathogens. 7: e1002209. PMID 21980282 DOI: 10.1371/Journal.Ppat.1002209  0.331
2011 Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, Bhattacharya T, Gnanakaran S, Daniels M, Haynes BF, Korber BT, Hahn BH, Shaw GM, Letvin NL. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. Plos One. 6: e23673. PMID 21876761 DOI: 10.1371/Journal.Pone.0023673  0.315
2011 Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, Mascola JR, Letvin NL. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. Journal of Virology. 85: 6906-12. PMID 21593181 DOI: 10.1128/Jvi.00326-11  0.388
2011 Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine. 3: 81ra36. PMID 21543722 DOI: 10.1126/Scitranslmed.3002351  0.33
2011 Whitney JB, Asmal M, Geiben-Lynn R. Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication. Plos One. 6: e18589. PMID 21533265 DOI: 10.1371/Journal.Pone.0018589  0.359
2011 Asmal M, Sun Y, Lane S, Yeh W, Schmidt SD, Mascola JR, Letvin NL. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. Journal of Virology. 85: 5465-75. PMID 21450829 DOI: 10.1128/Jvi.00313-11  0.343
2010 Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, Asmal M, Miljkovic S, Daniels M, Whitney JB, Keele BF, Hahn BH, Korber BT, Shaw GM, Seaman MS, et al. Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. Journal of Virology. 84: 6018-32. PMID 20357097 DOI: 10.1128/Jvi.02741-09  0.313
2009 Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, Buzby AP, Montefiori DC, Korber BT, Letvin NL. Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. Journal of Virology. 83: 2686-96. PMID 19129440 DOI: 10.1128/Jvi.02237-08  0.373
2009 Yeh W, Rahman I, Hraber P, Giri A, Nevidomskyte D, Coffey R, Asmal M, Miljkovic S, Whitney J, Keele B, Shaw G, Korber B, Seaman, Letvin N. P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys. Retrovirology. 6: 24. DOI: 10.1186/1742-4690-6-S3-P24  0.307
2008 Asmal M, Factor R, Walensky R. An HIV‐Infected Man with an Upset Stomach Clinical Infectious Diseases. 47: 979-980. DOI: 10.1086/591695  0.348
2005 Colgan J, Asmal M, Yu B, Luban J. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. Journal of Immunology (Baltimore, Md. : 1950). 174: 6030-8. PMID 15879096 DOI: 10.4049/Jimmunol.174.10.6030  0.574
2004 Colgan J, Asmal M, Neagu M, Yu B, Schneidkraut J, Lee Y, Sokolskaja E, Andreotti A, Luban J. Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity. 21: 189-201. PMID 15308100 DOI: 10.1016/J.Immuni.2004.07.005  0.659
2003 Asmal M, Colgan J, Naef F, Yu B, Lee Y, Magnasco M, Luban J. Production of ribosome components in effector CD4+ T cells is accelerated by TCR stimulation and coordinated by ERK-MAPK. Immunity. 19: 535-48. PMID 14563318 DOI: 10.1016/S1074-7613(03)00268-1  0.588
2000 Colgan J, Asmal M, Luban J. Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability. Genomics. 68: 167-78. PMID 10964515 DOI: 10.1006/Geno.2000.6295  0.563
Show low-probability matches.